HOME >> MEDICINE >> NEWS
Brookhaven Lab and BioSET develop a synthetic peptide that enhances the effect of BMP-2

UPTON, NY Researchers from the U.S. Department of Energy's Brookhaven National Laboratory (BNL) and BioSurface Engineering Technologies, Inc. (BioSET) have developed a synthetic peptide that enhances the effects of a tissue growth factor known as bone morphogenetic protein 2, or BMP-2. BMPs are a family of proteins in the human body responsible for the proliferation, repair, and differentiation of cells in many tissues, including bone.

The researchers designed one portion of the peptide to target the BMP-2 receptor molecules that occur on the surface of bone-forming stem cells and another portion to interact with BioSET's drug-binding agent HepaSilTM, a heparin-based product. The peptide, called B2A2, is one of a series of synthetic analogs of naturally occurring growth factors being developed in the Brookhaven/BioSET collaboration.

This research is reported in the November 8th online version of the Journal of Bone & Mineral Research.

"Our study shows that a small amount of the peptide that we developed increases the effectiveness of BMP-2 as much as 40 times," said Brookhaven scientist Louis Pea, senior author of the paper. "This peptide unlocks a synergy with BMP-2. In a cell culture model, we used BMP at doses too low to have any observable effect by itself, and the same was true for the B2A2 peptide. But when the two were added together in the same low doses, the cells were strongly triggered to develop into bone-forming cells.

"First-generation BMP-impregnated medical devices are currently used clinically for spine repair and to accelerate the healing of long bones," Pea continued. "These devices show effectiveness in inducing bone repair, but there is concern over the high levels of the growth factors that are currently required. An agent that decreases the amount of BMP needed or one that can recruit the body's own growth factors to be more effective could have a substantial clinic
'"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
9-Nov-2004


Page: 1 2

Related medicine news :

1. Brookhaven spotlights: News from the March 2003 American Chemical Society Meeting
2. Brookhaven lab scientist wins Glenn T. Seaborg Award for Nuclear Chemistry
3. Late developers may run higher risk of infection than sexually mature younger teens
4. Hospital acquired infections present major problem for infants in developing countries
5. Targeting mutant B-Raf protein reduces melanoma development
6. Liverpool to lead 20M Department of Health initiative to develop medicines for children
7. Helping answer needs by developing specialists in autism
8. Common anesthetics appear safe for developing fetal brain
9. UCSD-Utah team develops mouse model to test therapies for macular degeneration
10. Hopkins convenes consensus conference to develop blueprint for nationwide matching program
11. Daily supplement may boost birthweight of babies in the developing world

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2020)... TORONTO (PRWEB) , ... June 02, 2020 , ... ... Co-Founder, MiNA Therapeutics and Jacques Fieschi, PhD, VP of R&D, HalioDx ... EDT (4pm BST/UK). , Assessing the tumor microenvironment has proved to be ...
(Date:5/30/2020)... , ... May 29, 2020 , ... In appreciation for ... more than ever, James Hodge Hyundai is offering a $500 bonus towards the lease ... of this incentive now through January 4, 2021. , To qualify for this offer, ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... it is now manufacturing face shields to be used as personal protective ... COVID-19. These face shields are single use, made to be worn by frontline ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... availability of two leading RevSpring solutions—Talksoft® patient messaging and IVR Advantage™--for Loyale ... engaging patients through automated and precise texts, IVR reminders and email messages ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... Clinical Research, CenterWatch eLearning , https://www.centerwatch.com/products/category/2764-elearning/product/472-the-crc-trainer , Wherever one falls ... Companion to the CRC’s Guide to Coordinating Clinical Research provides the perfect ...
Breaking Medicine News(10 mins):
(Date:6/3/2020)... ... 2020 , ... Axiom Medical, a longtime leader in occupational ... a first of its kind technology providing workplace point-of-entry protection and case management ... easy self-service health attestation for organizations needing to pre-screen team members for potentially ...
(Date:6/2/2020)... ... 02, 2020 , ... Adoptive cell therapies have ushered in ... of two Chimeric Antigen Receptor T-Cell (CAR-T) therapies in 2017. In addition to ... (TCR-Ts), Natural Killer (NKs) cells and Dendritic Cells (DCs). , In this webinar, ...
(Date:6/2/2020)... ... June 02, 2020 , ... Aniara Diagnostica, a multi-national ... its commitment to meeting today’s highest standards for product quality and cost-efficient delivery. ... stages of drug discovery, screening of chemical, cosmetic, alimentary, or agrochemical compounds, and ...
Breaking Medicine Technology:
Cached News: